Table 5. Multivariate analysis for irPFS with ICIs therapy.

Parameters	HR	95% CI	P
irPFS, immunotherapy-related progression-free survival; ICI, immune checkpoint inhibitor; CLDN18.2, claudin 18 isoform 2; EBV, Epstein-Barr virus; pos, positive; neg, negative; HER2, epidermal growth factor receptor 2; TMB, tumor mutational burden; PD-L1, programmed death-ligand 1; CPS, combined positive score; HR, hazard ratio; 95% CI, 95% confidence interval.
CLDN18.2 cut-off ≥2+, 40%
EBV-pos vs. -neg	1.094	0.280−4.268	0.897
HER2-pos vs.-neg	0.506	0.227−1.126	0.095
TMB≥10 vs. <10	1.243	0.361−4.285	0.730
Therapeutic line (≥2nd vs. 1st)	5.640	2.772−11.474	<0.001
CLDN18.2-pos vs. -neg	1.714	0.955−3.076	0.071
PD-L1 CPS≥1 vs. <1	0.961	0.384−2.520	0.972
CLDN18.2 cut-off ≥2+, 70%
EBV-pos vs. -neg	1.173	0.302−4.560	0.818
HER2-pos vs.-neg	0.463	0.220−1.045	0.054
TMB≥10 vs. <10	1.202	0.350−4.127	0.770
Therapeutic line (≥2nd vs. 1st)	5.407	2.677−10.922	<0.001
CLDN18.2-pos vs. -neg	1.449	0.846−2.483	0.177
PD-L1 CPS≥1 vs. <1	0.925	0.519−1.650	0.792